MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
DarioHealth Corp. Cost of Revenue 2011-2026 | DRIO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue DarioHealth Corp.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.4 M | 18 M | 16.6 M | 5.06 M | 4.96 M | 5.63 M | 3.86 M | - | 1.68 M | 2.27 M | - | 1.04 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18 M | 1.04 M | 7.34 M |
Quarterly Cost of Revenue DarioHealth Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.99 M | 2.4 M | 2.87 M | - | 3.55 M | 3.5 M | 3.33 M | - | 2.91 M | 4.08 M | 3.9 M | - | 4.8 M | 5.04 M | 4.07 M | - | 4.8 M | 3.03 M | 1.99 M | - | 1.49 M | 1.15 M | 888 K | - | 995 K | 1.32 M | 1.68 M | - | 1.41 M | 1.54 M | 1.2 M | - | 1.1 M | 850 K | - | - | 652 K | 826 K | 670 K | - | 404 K | 410 K | 297 K | - | 585 K | 605 K | 421 K | - | - | - | 259 K | - | 272 K | 185 K | 161 K | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.04 M | 161 K | 1.84 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
6.6 M | $ 19.02 | 0.21 % | $ 99.4 M |  Israel |
 |
Co-Diagnostics
CODX
|
4.18 M | $ 0.17 | -6.7 % | $ 4.99 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 20.15 | -2.3 % | $ 217 M |  China |
 |
Danaher Corporation
DHR
|
9.67 B | $ 228.92 | -0.76 % | $ 167 B | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
1.33 B | $ 66.37 | -1.03 % | $ 25.6 B | USA |
 |
BioNano Genomics
BNGO
|
30.4 M | $ 1.53 | 2.0 % | $ 1.94 M | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 38.9 | -1.04 % | $ 1.08 B | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
IQVIA Holdings
IQV
|
10 B | $ 225.41 | -1.0 % | $ 40.9 B | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
221 M | $ 101.56 | -0.33 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 26.27 | -0.83 % | $ 794 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Myriad Genetics
MYGN
|
252 M | $ 6.15 | -0.32 % | $ 557 M | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 18.84 | -1.21 % | $ 1.01 B | USA |
 |
NeoGenomics
NEO
|
370 M | $ 11.76 | -3.84 % | $ 1.49 B | USA |
 |
Precipio
PRPO
|
9.18 M | $ 22.98 | -1.84 % | $ 29.8 M | USA |
 |
Personalis
PSNL
|
57.8 M | $ 7.96 | -0.13 % | $ 472 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Aspira Women's Health
AWH
|
3.86 M | - | -6.19 % | $ 10.5 M | USA |
 |
ENDRA Life Sciences
NDRA
|
173 K | $ 4.53 | -4.83 % | $ 2.43 M | USA |
 |
Soleno Therapeutics
SLNO
|
1.51 M | $ 46.3 | 0.02 % | $ 1.86 B | USA |
 |
Illumina
ILMN
|
1.51 B | $ 131.16 | -1.2 % | $ 20.9 B | USA |
 |
Trinity Biotech plc
TRIB
|
54.9 M | $ 0.79 | -3.54 % | $ 61.9 M |  Irlanda |
 |
Quest Diagnostics Incorporated
DGX
|
6.63 B | $ 173.53 | -1.12 % | $ 19.3 B | USA |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
9.38 B | $ 250.88 | -0.87 % | $ 21 B | USA |
 |
Twist Bioscience Corporation
TWST
|
186 M | $ 31.72 | -1.34 % | $ 1.9 B | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 182.22 | -0.43 % | $ 15 B | Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.52 B | $ 676.53 | -0.85 % | $ 55.8 B | USA |
 |
Lantheus Holdings
LNTH
|
546 M | $ 66.55 | -0.91 % | $ 4.61 B | USA |